3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Leukemia
42
Leukemia, Lymphocytic, Chronic, B-Cell
41
Lymphoma
30
Myelodysplastic Syndromes
24
Precursor Cell Lymphoblastic Leukemia-Lymphoma
19
Lymphoma, Non-Hodgkin
18
Hodgkin Disease
18
Leukemia, Myeloid, Acute
17
Multiple Myeloma
16
Myeloproliferative Disorders
14
Lymphoma, Mantle-Cell
10
Lymphoma, Follicular
10
Neoplasms, Plasma Cell
9
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma, B-Cell, Marginal Zone
9
Leukemia, Myeloid, Chronic-Phase
9
Congenital Abnormalities
9
Lymphoma, T-Cell, Peripheral
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Hematologic Neoplasms
8
Burkitt Lymphoma
8
Anemia, Aplastic
8
Waldenstrom Macroglobulinemia
7
Recurrence
7
Myelodysplastic-Myeloproliferative Diseases
7
Lymphoma, Large-Cell, Immunoblastic
7
Primary Myelofibrosis
6
Leukemia, Myelomonocytic, Chronic
6
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
6
Leukemia, Myeloid, Accelerated Phase
6
Interventions
teriflunomide
1
Vitamin D
1
Natalizumab
1
Fingolimod Hydrochloride
1
Dimethyl Fumarate
1
Cholecalciferol
1
Calcifediol
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Multiple Sclerosis, Relapsing-Remitting
×
Alemtuzumab
×
Clear all
NCT06705608
2024-11-26
MS; FTY720
University of British Columbia
Completed
4,000 enrolled